Literature DB >> 12441016

Pericardial disease in the oncology patient.

Avi S Retter1.   

Abstract

Malignant pericardial disease is a serious and common problem seen in patients with cancer. It is usually due to metastatic spread of the underlying malignancy or a complication of radiation therapy. The patient may have a mild, subtle presentation, as is often seen in the early stages of pericardial effusion, or may experience dramatic hemodynamic compromise, as is seen with cardiac tamponade and constrictive pericarditis. There are many treatment options available that range from simple drainage to thoracic surgery. It is essential that the treating physician choose a treatment plan in the context of the cancer stage and the patient's prognosis. This article discusses the incidence, pathophysiology, clinical presentation, diagnosis, and treatment options in the various types of malignant pericardial disease.

Entities:  

Mesh:

Year:  2002        PMID: 12441016     DOI: 10.1097/00132580-200211000-00008

Source DB:  PubMed          Journal:  Heart Dis        ISSN: 1521-737X


  5 in total

1.  Ultrasound-Guided Emergency Pericardiocentesis of a Patient with Multiple Myeloma in a Resource Limited Setting.

Authors:  Arpith-Easo Samuel; Reshma-Balembi Krishna
Journal:  Adv J Emerg Med       Date:  2017-11-30

Review 2.  Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography.

Authors:  Maurizio Galderisi; Francesco Marra; Roberta Esposito; Vincenzo Schiano Lomoriello; Moira Pardo; Oreste de Divitiis
Journal:  Cardiovasc Ultrasound       Date:  2007-01-25       Impact factor: 2.062

3.  Survival post surgery for malignant pericardial effusion.

Authors:  Olivier Nguyen; Denise Ouellette
Journal:  Clin Pract       Date:  2011-05-30

Review 4.  Diagnosis, treatment, and management of pericardial effusion- review.

Authors:  Naser Yamani; Ayesha Abbasi; Talal Almas; Farouk Mookadam; Samuel Unzek
Journal:  Ann Med Surg (Lond)       Date:  2022-07-09

Review 5.  Thoracic complications and emergencies in oncologic patients.

Authors:  Leslie E Quint
Journal:  Cancer Imaging       Date:  2009-10-02       Impact factor: 3.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.